Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Role of I/O Combination Therapies in mCRC

June 29th 2020

Using I/O in MSI-H Tumors in mCRC

June 29th 2020

Sequencing in mCRC: Later-Line Therapies

June 29th 2020

Therapeutic Agents in Relapsed/Refractory mCRC

June 29th 2020

CORRECT, RECOURSE, and ReDOS Trials in mCRC

June 29th 2020

Later Lines of Therapy for mCRC

June 29th 2020

Second-Line Treatment for mCRC

June 29th 2020

Initiating Therapy for mCRC

June 29th 2020

Continuum of Care for Metastatic CRC

June 29th 2020

Dr. Wang on Challenges With Checkpoint Inhibitors in CRC

June 23rd 2020

Timothy Cragin Wang, MD, discusses the lack of response to checkpoint inhibitors in colorectal cancer.

Dr. Kopetz on Safety Data From BEACON CRC Trial in BRAF V600E-Mutant mCRC

June 23rd 2020

Scott Kopetz, MD, PhD, FACP, discusses the safety data reported from the phase 3 BEACON CRC trial in BRAF V600E-mutant metastatic colorectal cancer.

FDA Grants Fruquintinib Fast Track Status for mCRC

June 18th 2020

The FDA has granted a fast track designation to fruquintinib for the treatment of patients with metastatic colorectal cancer who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, VEGF-directed therapy, and EGFR-directed therapy.

Siena Showcases Trastuzumab Deruxtecan Activity in HER2-Expressing mCRC

June 9th 2020

Salvatore Siena, MD, further discusses the DESTINY-CRC01 trial with trastuzumab deruxtecan and projects the impact of these findings on patients with HER2-expressing metastatic CRC.

Ensituximab Shows Modest Single-Agent Activity in CRC, Combinations to Be Explored

June 8th 2020

The novel chimeric monoclonal antibody ensituximab demonstrated modest clinical activity and was found to be well tolerated in patients with heavily pretreated, refractory colorectal cancer.

Dr. Nelson on the Future Utility of ctDNA in CRC

June 5th 2020

Douglas A. Nelson, MD, discusses the future utility of circulating tumor DNA in colorectal cancer.

Dr. Armaghany on the Utility of ctDNA in CRC

June 4th 2020

Tannaz Armaghany, MD, discusses the utility of circulating tumor DNA in colorectal cancer.

Encorafenib Plus Cetuximab Approved in Europe for BRAF V600E-Mutant mCRC

June 3rd 2020

The European Commission has approved encorafenib (Braftovi) in combination with cetuximab (Erbitux) for the treatment of adult patients with BRAF V600E–mutant metastatic colorectal cancer who have received prior systemic therapy.

Continued OS Advantage With Encorafenib/Cetuximab Cements Role in BRAF+ mCRC

June 3rd 2020

Scott Kopetz, MD, PhD, FACP, discusses the latest findings from the BEACON CRC study, the importance of testing for BRAF mutations in patients with CRC, and future directions with these agents.

Dr. Andre on the Rationale for the KEYNOTE-177 Trial in mCRC

June 3rd 2020

Thierry Andre, MD, discusses the rationale for the phase 3 KEYNOTE-177 trial in metastatic colorectal cancer.

Dr. Overman on Potential Application of ctDNA in CRC

June 2nd 2020

Michael J. Overman, MD, discusses potential applications for circulating tumor DNA in colorectal cancer.